Individual and combined contributions of age-specific and sex-specific pulse pressure and brachial-ankle pulse wave velocity to the risk of new-onset diabetes mellitus

Yuntao Wu, Xu Han, Jingli Gao, Yanxiu Wang, Chenrui Zhu, Zhe Huang, Aijun Xing, Shuo Huang, Mengyi Zheng, Qian Liu, Yaohua Tian, Shouling Wu

ABSTRACT

Introduction We aimed to investigate the individual and combined effects of age-specific and sex-specific pulse pressure (PP) and brachial-ankle pulse wave velocity (baPWV) on the incidence of new-onset diabetes mellitus.

Research design and methods Participants in the Kailuan study cohort who were ≥20 years old, participated in follow-up assessments and underwent baPWV measurements in 2010–2011, 2012–2013, and 2014–2015 were studied. The participants were allocated to four groups according to their PP and baPWV status, each categorized as high or normal, according to age-specific and sex-specific median values. Cox proportional hazards models were used to explore the individual and combined effects of PP and baPWV on the incidence of diabetes mellitus.

Results There were 18,619 participants who were followed for 4.27±1.91 years. A total of 877 new cases of diabetes were identified, and the incidence density was 11.03/1000 per year. Using the normal PP and normal baPWV group as the reference group, the multivariable-adjusted HRs and 95% CIs for diabetes mellitus were as follows: 1.08 (0.93 to 1.25) and 1.64 (1.41 to 1.90), respectively. Compared with the normal PP/baPWV group, the HR and 95% CI for diabetes in the high PP/baPWV, the high PP/normal baPWV, and high PP/baPWV groups were 1.66 (1.35 to 2.05), 1.09 (0.86 to 1.37), and 1.74 (1.43 to 2.13), respectively.

Conclusions High baPWV was independently associated with a higher risk of diabetes mellitus, and individuals with both high baPWV and high PP were at a still higher risk of diabetes mellitus.

INTRODUCTION

Diabetes mellitus is a chronic non-communicable disease that is highly prevalent worldwide. A recent study estimated that there are 463 million people around the world who have diabetes and predicted that this number will reach 700 million by 2045. Because of continuing social and economic advances, the prevalence of this disease in China is steadily increasing. A national survey conducted in 2013 generated estimated prevalences of diabetes and pre-diabetes in China of 10.9% and 35.7%, respectively. Diabetes is a risk factor for cardiocerebrovascular events and is associated with other complications, such as nephropathy, retinopathy, and peripheral vascular disease, which create significant social and economic burdens.

The etiology of diabetes is not yet clear. Heredity, physical inactivity, and a poor diet are well-known risk factors for diabetes. Arterial stiffness has also been shown to be a risk factor for diabetes in a large number of studies. Yasuno et al. found that high pulse pressure (PP) is a predictor of new-onset diabetes mellitus.
diabetes in hypertensive patients, and Zhang et al. showed that PP and brachial-ankle pulse wave velocity (baPWV) are associated with a higher risk of diabetes in hypertensive adults. Both PP and pulse wave velocity (PWV) are indicators of arterial stiffness, but the information they provide differs. BaPWV reflects both central and peripheral arterial stiffness, and PP only reflects central arterial stiffness, but changes in peripheral arteries do not significantly affect PP. In addition, some previous studies have shown that the individual effects of PP and PWV on the risks of cardiovascular events differ and that the two variables also have a combined effect on the incidences of such events.

In previous studies, the associations of PP and PWV with diabetes have been separately evaluated. However, to date, the combined effect of PP and baPWV on the risk of diabetes has not been evaluated. Arterial stiffness reflects the degeneration of the vascular elastic arterial extracellular matrix and is associated with age and sex. Therefore, the age and sex of the individual should be taken into account when PP and PWV are used to evaluate arterial stiffness. In the present study, we aimed to determine the combined effect of PP and baPWV on the incidence of new-onset diabetes using data from the Kailuan Study.

RESEARCH DESIGN AND METHODS

Study participants
The Kailuan Study is a longitudinal cohort study of current and retired employees of the Kailuan Group in Tangshan city, China. Between 2006 and 2007, the first health evaluations of employees and retirees of the Kailuan Group were conducted at Kailuan General Hospital and its 11 associated hospitals, and they were followed up every 2 years. A total of 101,510 participants were enrolled for the baseline survey. All the participants completed a standardized questionnaire and underwent physical examinations and laboratory testing. Between 2010 and 2011, baPWV was measured in some participants, and the full cohort underwent routine follow-up examinations. A total of 21,529 individuals participated in the follow-up evaluations between 2010 and 2015 and underwent baPWV measurement for the present study. Participants with diabetes (n=2795) or atrial fibrillation (n=47) were excluded, as well as those for whom blood pressure data were missing (n=12), and those who were lost to follow-up (n=56), which left data from 18,619 participants for analysis (figure 1). The study was performed according to the principles of the Declaration of Helsinki. Written informed consent was obtained from all the participants.

Measurement of blood pressure
Blood pressure was measured in the right brachial artery using a calibrated mercury column sphygmomanometer three times at intervals of 1–2 min, after the participants had rested for at least 5 min. If the difference between two values was >5 mm Hg, the blood pressure was remeasured. The mean of the three values was recorded. The HEM-8102A electronic sphygmomanometers used, which were manufactured by Omron Co, Ltd (Dalian, China), have been used since 2014. PP was calculated as the difference between the systolic and diastolic pressure. Mean arterial pressure (MAP) was calculated as the diastolic pressure plus one third pulse pressure.

Measurement of baPWV
BaPWV was measured between 07:00 and 09:00 hours on the day of the follow-up examination by trained professionals. The examination room temperature was kept between 22°C and 25°C. A BP-203RPEIII network arterial stiffness detection device (Omron Health Medical Co, Ltd) was used to make measurements in all four limbs, from which baPWV was calculated. In this study, baPWV was calculated as La–Lb/ΔT, in which La is the distance from the heart to the ankle, Lb is the distance from the heart to the brachium, and ΔT is the time interval between the wavefront of the brachial waveform and that of the ankle waveform. Participants were required to rest for at least 5 min beforehand, were not permitted to smoke, and had to lie down during the measurements. Bilateral measurements were made twice in each individual and the higher value (left or right) made on the second occasion was recorded as the baPWV. In a validation study, three measurements were made three times in 77 participants, following the standard procedure. We calculated the intraclass correlation coefficient (ICC) to assess test–retest reliability; all the pairs showed good (ICC ≥0.40) to excellent (ICC ≥0.75) reliability.
Assessment of diabetes status

All the participants provided venous blood samples after an overnight fast of 8–12 hours. Fasting blood glucose (FBG) concentration was measured using the hexokinase/glucose-6-phosphate dehydrogenase method on an autoanalyzer (Hitachi 747; Hitachi, Tokyo, Japan) in the central laboratory of Kailuan General Hospital. The coefficient of variation, calculated using blind quality control specimens, was <2.0%. Information regarding treatment with insulin or oral hypoglycemic agents was collected during follow-up.

Incident diabetes was defined as a self-reported physician diagnosis of diabetes during the follow-up period, the use of glucose-lowering drugs during the follow-up period, or a change in FBG from <7.0 mmol/L at baseline to ≥7.0 mmol/L at the final visit. Patients with pre-existing diabetes, defined as a self-reported history of diabetes mellitus, the administration of antidiabetic medication, or an FBG ≥7.0 mmol/L at baseline, were excluded. The participants were followed from the day their baPWV was measured until a diagnosis of incident diabetes was made, they were lost to follow-up because of emigration or death, or the end of the follow-up period.

Assessment of covariates

Epidemiologic, anthropometric, biochemical, and lifestyle survey data for the participants have been published previously. Information regarding their age, sex, smoking habits, alcohol intake, salt intake, physical activity, income, educational level, and medical history, including the presence of hypertension or diabetes, and the use of medication, such as hypoglycemic agents, antihypertensive agents, lipid-lowering agents, or aspirin, was collected using questionnaires. The height, body mass, and heart rate of the participants were measured by a nurse. Body mass index (BMI) was calculated as body mass in kilograms divided by the square of height in meters. Serum total cholesterol, triglyceride, high-density lipoprotein-cholesterol, low-density lipoprotein-cholesterol, and high-sensitivity C reactive protein (hs-CRP) concentrations were measured using an automatic analyzer (Hitachi 747; Hitachi, Tokyo, Japan) in the Central Laboratory of Kailuan Hospital.

Statistical analysis

Baseline data were collected during the visit at which baPWV was measured. As in a previous study, the participants were allocated to four groups according to their PP and baPWV, which were categorised as normal or high on the basis of age-specific and sex-specific median values: (1) a normal PP/baPWV group; (2) a normal PP/high baPWV group; (3) a high PP/normal baPWV group; and (4) a high PP/baPWV group. The relationship between baPWV and PP was evaluated using Pearson’s correlation coefficient. The cumulative incidence of diabetes in each group was calculated using the Kaplan-Meier method and was also compared using the log-rank test.

Multivariable Cox proportional hazards models were used to evaluate the relationships between the four groups and the incidence of diabetes and to evaluate the individual relationships between PP or baPWV and the incidence of diabetes. We determined whether there was a statistical interaction between the exposure categories (normal or high PP and normal or high baPWV) by entering these variables as interaction terms into the multivariable models. We adjusted for age, sex, BMI, mean arterial pressure, serum hs-CRP concentration, smoking status, alcohol consumption status, physical activity, hyperlipidemia, family history of diabetes, and the use of antihypertensive agents in the multivariable models. The covariates were selected on the basis of previous reports of their association with diabetes in China.

Several sensitivity analyses were performed to test the robustness of the results. Because some antihypertensive agents, for example, diuretics and some β-blockers, and lipid-lowering agents can adversely affect glucose metabolism, we excluded participants who used cholesterol-lowering agents and antihypertensive agents during the follow-up period. We also excluded individuals with ankle-brachial index ≤0.9 at baseline, because arterial stenosis or occlusion in a lower extremity can affect the accuracy of baPWV measurements. We also performed subgroup analyses according to sex and age. To assess the potential confounding effects of pre-diabetes and gestational diabetes, we performed two sensitivity analyses that separately excluded pre-diabetic patients and gestational diabetes.

RESULTS

Table 1 shows the baseline characteristics of each group. The mean age of the participants was 47.65 (SD: 12.32) years, and 12 458 (66.91%) of them were male. The median PP and baPWV were 44.67 mm Hg and 1405.00 cm/s, respectively. The age-specific and sex-specific median PP and baPWV values are shown in online supplemental table 1. There were 7488 participants (40.22%) who were discordant with respect to PP and baPWV status (3506 with normal PP and high baPWV, and 3982 with high PP and normal baPWV). The correlation coefficient for the relationship between PP and baPWV was 0.33 after adjustment for age and sex.

Cumulative incidence of diabetes

The length of the follow-up period was 4.27±1.91 years, and the number of follow-up visits was 2.94±0.89. During this period, a total of 877 participants developed diabetes, yielding a cumulative incidence of 8.86% and an incidence density of 11.03/1000 persons per year. The cumulative incidences for the normal and high PP groups were 8.82% and 10.75%, and those for the normal baPWV and high baPWV groups were 6.61% and 12.86%, respectively. The cumulative incidences of diabetes were 6.53%,
Comparison of the risk of new-onset diabetes in each group

Compared with the normal PP group, the high PP group had a significantly higher risk of developing diabetes, according to model 1. However, in models 2 and 3, high PP was not significantly associated with the risk of diabetes (HR 1.08; 95% CI 0.93 to 1.25) (table 2). Compared with the normal baPWV group, the high baPWV group had a significantly higher risk of diabetes, according to models 1 and 2, and after adjustment for PP in model 3, an association between baPWV and the risk of diabetes remained (HR 1.08; 95% CI 0.93 to 1.25) (table 3).

Table 4 shows the risk of diabetes in each of the groups. In the multivariable-adjusted model, the HRs for new-onset diabetes were significantly higher in the normal PP/high baPWV (HR 1.66, 95% CI 1.35 to 2.05) and high PP/normal baPWV (HR 1.74, 95% CI 1.43 to 2.13) groups than in the normal PP/baPWV group. In subgroup analyses, no significant associations were found among female participants alone (online supplemental tables 3–6). In addition, the effect estimates were not significantly affected by the exclusion of patients with pre-diabetes or gestational diabetes (online supplemental tables 7 and 8).

**DISCUSSION**

In the present study, we used age-specific and sex-specific cut-off values to define high and normal PP and baPWV and found that high baPWV was associated with a higher risk of diabetes, whereas high PP was not. However, when combinations of high or normal PP and baPWV were considered, we found that participants with both high baPWV and high PP were at the highest risk.

The present results are consistent with those of previous studies that showed that arterial stiffness increases the risk of diabetes. Muhammad et al15 used carotid-femoral pulse wave velocity (cfPWV) as an indicator of arterial stiffness and found that the risk of diabetes in people with high cfPWV was 3.24 times higher than in those with low cfPWV. In addition, a prospective study of 2,429 hypertensive patients showed that baseline baPWV is positively associated with the risk of developing diabetes.3 More recently, Liu et al86 found that there is a dose–response

### Table 1 Baseline characteristics of participants by PP and baPWV status

<table>
<thead>
<tr>
<th></th>
<th>Total population n=18619</th>
<th>Normal PP and normal baPWV n=5295</th>
<th>Normal PP and increased baPWV n=3506</th>
<th>Increased PP and normal baPWV n=3982</th>
<th>Increased PP and increased baPWV n=5836</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age (year)</strong></td>
<td>47.65±12.32</td>
<td>47.99±12.26</td>
<td>46.89±12.62</td>
<td>47.01±12.34</td>
<td>48.24±12.13</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>Male (%)</strong></td>
<td>12.45 (66.91)</td>
<td>3644 (68.82)</td>
<td>2437 (69.51)</td>
<td>2563 (64.36)</td>
<td>3814 (65.35)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>SBP (mm Hg)</strong></td>
<td>127.96±18.07</td>
<td>115.62±12.55</td>
<td>121.76±13.34</td>
<td>131.07±15.07</td>
<td>140.75±17.49</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>DBP (mm Hg)</strong></td>
<td>81.70±10.91</td>
<td>78.59±9.56</td>
<td>83.67±10.59</td>
<td>78.77±10.35</td>
<td>85.32±11.25</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>PP (mm Hg)</strong></td>
<td>46.26±12.52</td>
<td>37.03±6.97</td>
<td>38.09±6.71</td>
<td>52.30±9.73</td>
<td>55.42±11.77</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>BaPWV (cm/s)</strong></td>
<td>1466.99±321.18</td>
<td>1283.23±181.77</td>
<td>1602.27±303.47</td>
<td>1293.32±184.92</td>
<td>1670.95±341.60</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>BMI (kg/m²)</strong></td>
<td>24.71±3.36</td>
<td>24.27±3.28</td>
<td>24.61±3.35</td>
<td>24.75±3.24</td>
<td>25.13±3.44</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>FBG (mmol/L)</strong></td>
<td>5.19±0.67</td>
<td>5.10±0.58</td>
<td>5.19±0.88</td>
<td>5.19±0.60</td>
<td>5.28±0.63</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>TC (mmol/L)</strong></td>
<td>5.02±1.60</td>
<td>4.94±1.87</td>
<td>5.00±1.32</td>
<td>4.99±1.38</td>
<td>5.13±1.62</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>TG (mmol/L)</strong></td>
<td>1.22 (0.84–1.84)</td>
<td>1.14 (0.80–1.68)</td>
<td>1.28 (0.89–2.00)</td>
<td>1.13 (0.78–1.71)</td>
<td>1.32 (0.90–2.01)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>LDL-C (mmol/L)</strong></td>
<td>2.64±0.90</td>
<td>2.56±0.92</td>
<td>2.63±1.04</td>
<td>2.64±0.81</td>
<td>2.72±0.83</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>HDL-C (mmol/L)</strong></td>
<td>1.50±0.71</td>
<td>1.50±0.45</td>
<td>1.49±0.71</td>
<td>1.50±0.66</td>
<td>1.50±0.90</td>
<td>0.822</td>
</tr>
<tr>
<td><strong>hs-CRP (mg/L)</strong></td>
<td>−0.55±2.62</td>
<td>−0.57±2.45</td>
<td>−0.47±2.56</td>
<td>−0.65±2.71</td>
<td>−0.51±2.74</td>
<td>0.012</td>
</tr>
<tr>
<td><strong>Smoking (%)</strong></td>
<td>6708 (36.03)</td>
<td>1943 (36.69)</td>
<td>1362 (38.85)</td>
<td>1300 (32.65)</td>
<td>2103 (36.03)</td>
<td>0.002</td>
</tr>
<tr>
<td><strong>Drinking (%)</strong></td>
<td>5727 (30.76)</td>
<td>1709 (32.28)</td>
<td>1186 (33.83)</td>
<td>1080 (27.12)</td>
<td>1752 (30.02)</td>
<td>0.007</td>
</tr>
<tr>
<td><strong>Exercise (%)</strong></td>
<td>1687 (9.06)</td>
<td>565 (10.67)</td>
<td>316 (9.01)</td>
<td>331 (8.31)</td>
<td>475 (8.14)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>Hypertension (%)</strong></td>
<td>6551 (35.18)</td>
<td>968 (18.28)</td>
<td>1211 (34.54)</td>
<td>1220 (30.64)</td>
<td>3152 (54.01)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>Blood pressure lowering agents (%)</strong></td>
<td>2311 (12.41)</td>
<td>321 (6.06)</td>
<td>461 (13.15)</td>
<td>361 (9.07)</td>
<td>1168 (20.01)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td><strong>Lipid-lowering drugs (%)</strong></td>
<td>164 (0.88)</td>
<td>36 (0.68)</td>
<td>37 (1.06)</td>
<td>25 (0.63)</td>
<td>66 (1.13)</td>
<td>0.013</td>
</tr>
</tbody>
</table>

P, comparison of baseline characteristics between different PP and baPWV groups.

*Log10 transformation.

baPWV, brachial-ankle pulse wave velocity; BMI, body mass index; DBP, diastolic blood pressure; FBG, fasting blood glucose; HDL-C, high-density lipoprotein cholesterol; hs-CRP, high-sensitivity C reactive protein; LDL-C, low-density lipoprotein cholesterol; PP, pulse pressure; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride.

12.04%, 6.24%, and 13.18% for the normal PP/baPWV, normal PP/high baPWV, high PP/normal baPWV, and high PP/baPWV groups, respectively (figure 2).
Cardiovascular and metabolic risk

relationship between baPWV and the risk of type 2 diabetes, and in a prospective cohort study conducted in China, it was shown that baPWV might be an independent predictor of new-onset type 2 diabetes. Consistent with these previous findings, the present results show that there is a 1.64-fold increase in the risk of developing diabetes in patients with a high baPWV.

Although several plausible biological pathways have been implicated, the mechanism underlying the link between baPWV and diabetes remains unclear. First, endothelial cell dysfunction could cause microvascular dysfunction, leading to poor tissue perfusion, impaired glucose metabolism and insulin resistance, and arterial stiffness. In addition, arterial stiffness might worsen

**Figure 2** Cumulative diabetes incidence in groups with combinations of normal or high PP and baPWV. p<0.05; log-rank test.

baPWV, brachial-ankle pulse wave velocity; PP, pulse pressure.

**Table 2** Risk of increased PP on the new-onset diabetes events

<table>
<thead>
<tr>
<th>Groups</th>
<th>N</th>
<th>Events</th>
<th>Incidence density (persons per year)</th>
<th>Model 1 HR (95% CI)</th>
<th>Model 2 HR (95% CI)</th>
<th>Model 3 HR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Increased PP</td>
<td>9818</td>
<td>498</td>
<td>12.31</td>
<td>1.41 (1.23 to 1.61)</td>
<td>1.13 (0.97 to 1.31)</td>
<td>1.08 (0.93 to 1.25)</td>
</tr>
<tr>
<td>Per SD increase in PP</td>
<td>18619</td>
<td>877</td>
<td>11.03</td>
<td>1.20 (1.13 to 1.28)</td>
<td>1.06 (0.98 to 1.15)</td>
<td>1.01 (0.93 to 1.09)</td>
</tr>
</tbody>
</table>

Model 1: adjusted for age and gender; model 2, adjusted for age, gender, BMI, MAP, hs-CRP, smoking, drinking, exercise, hyperlipidemia, family history of diabetes and blood pressure lowering agents; model 3: adjusted for all the variables in model 2 and baPWV.
cardiovascular and metabolic risk

Table 3  Risk of increased baPWV on the new-onset diabetes events

<table>
<thead>
<tr>
<th>Groups</th>
<th>N</th>
<th>Events</th>
<th>Incidence density (persons per year)</th>
<th>Model 1</th>
<th>Model 2</th>
<th>Model 3</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>HR (95% CI)</td>
<td>HR (95% CI)</td>
<td>HR (95% CI)</td>
</tr>
<tr>
<td>Normal baPWV</td>
<td>9277</td>
<td>306</td>
<td>7.65</td>
<td>Ref.</td>
<td>Ref.</td>
<td>Ref.</td>
</tr>
<tr>
<td>Increased baPWV</td>
<td>9342</td>
<td>571</td>
<td>14.44</td>
<td>1.96 (1.70 to 2.25)</td>
<td>1.65 (1.42 to 1.91)</td>
<td>1.64 (1.41 to 1.90)</td>
</tr>
<tr>
<td>Per SD increase in baPWV</td>
<td>18619</td>
<td>877</td>
<td>11.03</td>
<td>1.41 (1.33 to 1.49)</td>
<td>1.36 (1.27 to 1.46)</td>
<td>1.36 (1.27 to 1.46)</td>
</tr>
</tbody>
</table>

Model 1: adjusted for age and gender; model 2: adjusted for age, gender, BMI, MAP, hs-CRP, smoking, drinking, exercise, hyperlipidemia, family history of diabetes, blood pressure lowering agents; model 3, adjusted for all the variables in model 2 and PP.

baPWV, brachial-ankle pulse wave velocity; BMI, body mass index; hs-CRP, high-sensitivity C reactive protein; MAP, mean arterial pressure; PP, pulse pressure.

microvascular lesions, leading to the creation of a vicious circle. Second, whereas normal arteries buffer the PP, arterial stiffness leads to high blood flow through low-resistance organs, such as the brain and kidney, resulting in organ dysfunction. Furthermore, because the pancreas is a low-resistance, high-blood flow organ (mean tissue perfusion 250–300 mL/min/100 g), it may be that its endocrine function is adversely affected by arterial stiffness.

We did not find that high PP is associated with a higher risk of diabetes, which is consistent with the finding of Chen et al that PP was not associated with the risk of diabetes in a hypertensive population. In contrast, Yasuno et al found that PP is an independent predictor of new-onset diabetes in hypertensive patients in Japan. However, it is important to highlight that the present study was performed in the general population and that we recruited participants of a relatively young age (mean age 47 years). Chen et al also studied young hypertensive patients (mean age 41 years), whereas the mean age of the participants in the study by Yasuno et al was 64 years. In addition, we included the direct measures of arterial stiffness as a covariate in the analysis. These factors might explain the difference in the findings of the present study and that of Yasuno et al.

The correlation coefficient for the relationship between PP and baPWV was 0.33 after adjustment for age and sex. Kang et al and Kim et al made similar findings and obtained correlation coefficients of 0.44 and 0.36, respectively. In another study that used cfPWV as the measure of arterial stiffness, the correlation coefficient was 0.43, which implies that there is a difference between the use of PP and cfPWV for the evaluation of arterial stiffness. Furthermore, this study showed that the effects of cfPWV and PP on the risk of cardiovascular disease are additive, which is similar to the findings of the present study, in which the presence of both high PP and high baPWV further increased the risk of incident diabetes. We also found that individuals with normal PP and high baPWV and those with high PP and baPWV had higher risks of diabetes than those with normal PP and baPWV. However, individuals with high PP and normal baPWV did not have a significantly higher risk of diabetes. These results suggest that baPWV may be a better predictor of diabetes than PP.

The present study had several limitations. First, we used baPWV, rather than cfPWV, as a measure of arterial stiffness. However, baPWV closely correlates with cfPWV and has been widely used in studies of Asian populations. Second, a single population was studied; therefore, the results require validation in other populations. Third, diagnoses of diabetes were made on the basis of single measurements of FBG, which may have resulted in an underestimation of the incidence of diabetes. Finally, we did not differentiate patients with type 1 and type 2 diabetes. However, according to the Chinese clinical guidelines for the prevention of diabetes, type 2 diabetes represents about 95% of all cases.

In summary, we have shown that high baPWV is associated with a higher risk of diabetes, and individuals with both a high baPWV and a high PP have a still higher risk of diabetes. The measurement of baPWV in the general population may significantly contribute to the prevention of diabetes.

Table 4  Risk of different PP and baPWV combination on the new-onset diabetes events

<table>
<thead>
<tr>
<th>Groups</th>
<th>N</th>
<th>Events</th>
<th>Incidence density (persons per year)</th>
<th>Model 1</th>
<th>Model 2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>HR (95% CI)</td>
<td>HR (95% CI)</td>
</tr>
<tr>
<td>Normal PP and baPWV</td>
<td>5295</td>
<td>178</td>
<td>7.46</td>
<td>Ref.</td>
<td>Ref.</td>
</tr>
<tr>
<td>Normal PP and increased baPWV</td>
<td>3506</td>
<td>201</td>
<td>13.21</td>
<td>1.88 (1.53 to 2.30)</td>
<td>1.66 (1.35 to 2.05)</td>
</tr>
<tr>
<td>Increased PP and normal baPWV</td>
<td>3982</td>
<td>128</td>
<td>7.94</td>
<td>1.23 (0.98 to 1.54)</td>
<td>1.09 (0.86 to 1.37)</td>
</tr>
<tr>
<td>Increased PP and baPWV</td>
<td>5836</td>
<td>370</td>
<td>15.21</td>
<td>2.29 (1.91 to 2.73)</td>
<td>1.74 (1.43 to 2.13)</td>
</tr>
</tbody>
</table>

Model 1: adjusted for age and gender; model 2: adjusted for age, gender, BMI, MAP, hs-CRP, smoking, drinking, exercise, hyperlipidemia, family history of diabetes and blood pressure lowering agents.

baPWV, brachial-ankle pulse wave velocity; BMI, body mass index; hs-CRP, high-sensitivity C reactive protein; MAP, mean arterial pressure; PP, pulse pressure.
Author affiliations
1 Department of Cardiology, Kailuan General Hospital, North China University of Science and Technology, Tangshan, China
2 Graduate School, North China University of Science and Technology, Tangshan, China
3 Department of Maternal and Child Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Acknowledgements We would like to thank all of the staff members in the medical health check-up center at Kailuan Hospital, and we thank Mark Clasby, PhD, from Liwen Bianji, Edanz Group China (www.liwenbianji.cn/ac), for editing the English text of a draft of this manuscript.

Contributors XH and SW designed the study, YWu and XH performed statistical analysis and drafted the manuscript with assistance from YT, JG, YWu, CZ, ZH, AX, SC, YM, MZ and QL contributed to the specification of the analyses and critically reviewed and edited the manuscript. YWu and XH are the guarantors of this work and, as such, had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval This study was approved by the Ethics Committee of the Kailuan General Hospital (ChiCTR-TNC-11001489).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement No data are available. Proposals for collaborative research can be submitted to Wu(drwusl@163.com)

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

ORCID iDs Yuohua Tian http://orcid.org/0000-0002-9855-6991
Shouling Wu http://orcid.org/0000-0001-7095-6022

REFERENCES

Cardiovascular and metabolic risk

7

BMJ Open Diab Res Care published as 10.1136/bmjdrc-2020-001942 on 21 June 2021. Downloaded from http://dx.doi.org/10.1136/bmjdr...